Read by QxMD icon Read

Head and Neck cancer

shared collection
724 papers 100 to 500 followers
By Massimo Ghiani Medical Doctor involved in Head and neck cancer
M Roskies, E Kay-Rivest, M A Mascarella, K Sultanem, A Mlynarek, M Hier
BACKGROUND: A commonly employed treatment for advanced staged oropharyngeal squamous cell carcinoma (OPSCC) is concurrent radiation and chemotherapy with cisplatin as the gold standard. Carboplatin is reported to have the same radiopotentiation properties and a superior side effect profile; however, its use in head and neck cancer has been limited due to the paucity of data and reported hematologic side effects. In this study, we describe our institution's experience with carboplatin, paclitaxel and radiation in the treatment of oropharyngeal squamous cell carcinoma over a 10 year period...
October 10, 2016: Journal of Otolaryngology—Head & Neck Surgery
Dominik Schulz, Markus Wirth, Guido Piontek, Anna Maria Stefanie Buchberger, Jürgen Schlegel, Rudolf Reiter, Gabriele Multhoff, Anja Pickhard
Despite remarkable successes with targeted therapies in the treatment of cancer, resistance can occur which limits the clinical outcome. In this study, we generated and characterized resistant cell clones derived from two different head and neck squamous cell carcinoma (HNSCC) cell lines (Cal27, UD-SCC-5) by long-term exposure to five targeted- and chemotherapeutics (afatinib, MK2206, BEZ235, olaparib and cisplatin). The resistant tumor cell clones showed an increased ERK1/2 expression and an altered expression of the stem-cell markers CD44, ALDH1, Oct4, Sox2, Nanog and Bmi1...
2016: American Journal of Cancer Research
K Kırca, S Kutlutürkan
Radiotherapy is a reliable and effective treatment method for the treatment of head and neck cancers. This study was conducted as a descriptive work with the purpose of determining the symptoms experienced by patients with head and neck cancer who are undergoing radiotherapy. The study was carried out on 47 patients receiving treatment in oncology clinics. Data were obtained at mid-radiotherapy (RT), at the end of radiotherapy and 1 month after the end of radiotherapy using the Memorial Symptom Assessment Scale (MSAS) and Personal Information Forms...
October 10, 2016: European Journal of Cancer Care
Irene Göllnitz, Johanna Inhestern, Thomas G Wendt, Jens Buentzel, Dirk Esser, Daniel Böger, Andreas H Mueller, Jörn-Uwe Piesold, Stefan Schultze-Mosgau, Ekkehard Eigendorff, Peter Schlattmann, Orlando Guntinas-Lichius
To examine the impact of comorbidity on overall survival (OS) in a population-based study of patients with head and neck cancer who were treated between 2009 and 2011. Data of 1094 patients with primary head and neck carcinomas without distant metastasis from the Thuringian cancer registries were evaluated concerning the influence of patient's characteristics and comorbidity on OS. Data on comorbidity prior to head and neck cancer diagnosis was adapted to the Charlson Comorbidity (CCI), age-adjusted CCI (ACCI), head and neck CCI (HNCCI), simplified comorbidity score (SCS), and to the Adult Comorbidity Evaluation-27 (ACE-27)...
October 11, 2016: Cancer Medicine
Alexander T Falk, Christophe Hébert, Antoine Tran, Marie-Eve Chand, Axel Leysalle, Juliette Thariat, Olivier Dassonville, Gilles Poissonnet, Alexandre Bozec, Esma Saada, Fréderic Peyrade, Karen Benezery
Concomitant radiotherapy and cetuximab association has shown superiority to exclusive radiotherapy for head and neck cancers. Data on this association are scarce for the elderly population despite its rising incidence. A retrospective monocentric data collection was performed in the Antoine Lacassagne Cancer Center in France. Inclusion criteria were: age >70 years at time of diagnosis, histologically proven head and neck epidermoid carcinoma, treated with radiotherapy combined with cetuximab. Thirty-five patients were included between 2008 and 2012...
October 11, 2016: European Archives of Oto-rhino-laryngology
R L Ferris, J L Geiger, S Trivedi, N C Schmitt, D E Heron, J T Johnson, S Kim, U Duvvuri, D A Clump, J E Bauman, J P Ohr, W E Gooding, A Argiris
BACKGROUND: Treatment intensification for resected, high-risk, head and neck squamous cell carcinoma (HNSCC) is an area of active investigation with novel adjuvant regimens under study. In this trial, the epidermal growth-factor receptor (EGFR) pathway was targeted using the IgG2 monoclonal antibody panitumumab in combination with cisplatin chemoradiotherapy (CRT) in high-risk, resected HNSCC. PATIENTS AND METHODS: Eligible patients included resected pathologic stage III or IVA squamous cell carcinoma of the oral cavity, larynx, hypopharynx, or human-papillomavirus (HPV)-negative oropharynx, without gross residual tumor, featuring high-risk factors (margins <1 mm, extracapsular extension, perineural or angiolymphatic invasion, or ≥2 positive lymph nodes)...
October 11, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Caroline Brammer, Sundus Yahya, Dawn Dawson, Carol Glaister, Susan B Merrick
OBJECTIVES: The aim of this feasibility study is to define the resource effectiveness of Cetuximab versus cisplatin given concomitantly with radiotherapy for squamous cell carcinoma within a NHS clinical oncology unit. METHODS: 20 Patients with stage 3 or 4 head and neck squamous cell cancers were randomised to receive either Cetuximab with radiotherapy (ERT) or cisplatin with radiotherapy (CRT) concurrent with external beam radiotherapy 70 Gy in 35 fractions on a 1:1 basis over a 12-month duration...
October 13, 2016: British Journal of Radiology
P Morbini, M Benazzo
Human papillomavirus (HPV)-associated squamous cell carcinoma of the oropharynx is a well-defined entity mostly affecting young to middle-aged male non-smokers. It is generally associated with a favourable outcome, and for this reason a less intensive therapeutic approach has been proposed for this subset of patients. The incidence of HPV-associated oropharyngeal cancers is rapidly increasing in most Western countries, but detailed epidemiological data are not available for the Italian population. Furthermore, among other head and neck regions, a smaller proportion of oral high-grade dysplasia and cancers seems to depend on HPV infection, whereas its role in laryngeal cancer is recognised as less relevant...
August 2016: Acta Otorhinolaryngologica Italica
A Argiris, J E Bauman, J Ohr, W E Gooding, D E Heron, U Duvvuri, G J Kubicek, D M Posluszny, M Vassilakopoulou, S Kim, J R Grandis, J T Johnson, M K Gibson, D A Clump, J T Flaherty, S I Chiosea, B Branstetter, R L Ferris
BACKGROUND: We previously reported the safety of concurrent cetuximab, an antibody against epidermal growth factor receptor (EGFR), pemetrexed, and radiation therapy (RT) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). In this non-comparative phase II randomized trial, we evaluated this non-platinum combination with or without bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF). PATIENTS AND METHODS: Patients with previously untreated stage III-IVB SCCHN were randomized to receive: conventionally fractionated radiation (70 Gy), concurrent cetuximab, and concurrent pemetrexed (arm A); or the identical regimen plus concurrent bevacizumab followed by bevacizumab maintenance for 24 weeks (arm B)...
August 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Trille Kjaer, Susanne Oksbjerg Dalton, Elo Andersen, Randi Karlsen, Anni Linnet Nielsen, Merete Kjaer Hansen, Kirsten Frederiksen, Christoffer Johansen
BACKGROUND AND PURPOSE: To test the effect of longitudinal feedback on late effects reported by survivors of head-and-neck cancer (HNC) to clinicians during regular follow-up. MATERIAL AND METHODS: A total of 266 participants were sequentially assigned to either control or intervention group and filled in electronic versions of the EORTC QLQ C-30, H&N35, HADS and a study-specific list of symptoms at up to two consecutive follow-up visits. Participants' symptoms displayed according to severity were provided to the clinician for the intervention group but not for the control group...
May 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Patrick Lorimer, Zvonimir Milas
Most cutaneous malignancies of the head and neck (HN) are non-melanoma skin cancers, predominantly basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs). Less common entities include Merkel cell carcinoma (MCC), sebaceous carcinoma (SC), and angiosarcoma. Treatment is based on histology subtype, stage, and extent of involvement. Surgery is the primary means of treatment and includes wide local excision, Mohs micrographic surgery, sentinel lymph node biopsy, and cervical lymphadenectomy. Multidisciplinary management including radiation and targeted chemotherapy are critical adjuncts to surgery...
June 2016: Seminars in Oncology
Kathleen R Makielski, Denis Lee, Laurel D Lorenz, Dhananjay M Nawandar, Ya-Fang Chiu, Shannon C Kenney, Paul F Lambert
Epstein-Barr virus and human papillomaviruses are human tumor viruses that infect and replicate in upper aerodigestive tract epithelia and cause head and neck cancers. The productive phases of both viruses are tied to stratified epithelia highlighting the possibility that these viruses may affect each other's life cycles. Our lab has established an in vitro model system to test the effects of EBV and HPV co-infection in stratified squamous oral epithelial cells. Our results indicate that HPV increases maintenance of the EBV genome in the co-infected cells and promotes lytic reactivation of EBV in upper layers of stratified epithelium...
August 2016: Virology
Ho-Seob Kang, Jong-Lyel Roh, Sang-Wook Lee, Sung-Bae Kim, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim
The survival of patients with head and neck squamous cell carcinoma (HNSCC) can be affected not only by progression of the original cancer or occurrence of a second cancer but also by noncancer health event (NCHE). In this study, we evaluated the prognostic significance of early NCHEs in HNSCC patients after definitive radiotherapy (RT) or chemoradiotherapy (CRT).The prospective study cohort comprised 190 HNSCC patients who underwent definitive RT (n = 75) or CRT (n = 115). An early NCHE was defined as an event requiring hospital readmission of the patient within 12 months after treatment...
May 2016: Medicine (Baltimore)
Young Jun Choi, Jeong Hyun Lee, Yu Sub Sung, Ra Gyoung Yoon, Ji Eun Park, Soon Yuhl Nam, Jung Hwan Baek
Treatment failures in head and neck cancer patients are mainly related to locoregional tumor recurrence. The objective of the present study was to evaluate the diagnostic accuracy of model-free dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to detect local recurrence during the surveillance of head and neck cancer patients.Our retrospective study enrolled 24 patients with primary head and neck cancer who had undergone definitive treatment. Patients were grouped into local recurrence (n = 12) or posttreatment change (n = 12) groups according to the results of biopsy or clinicoradiologic follow-up...
May 2016: Medicine (Baltimore)
Nabil F Saba, Joseph K Salama, Jonathan J Beitler, Paul M Busse, Jay S Cooper, Christopher U Jones, Shlomo Koyfman, Harry Quon, John A Ridge, Farzan Siddiqui, Francis Worden, Min Yao, Sue S Yom
BACKGROUND: Nasopharyngeal carcinoma (NPC) presents mostly with locally advanced disease and is treated with multimodal therapy; however, consensus is lacking for different clinical scenarios. METHODS: The American College of Radiology (ACR) Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel...
July 2016: Head & Neck
Hung-Ming Wang, Chien-Yu Lin, Chia-Hsun Hsieh, Cheng-Lung Hsu, Kang-Hsing Fan, Joseph Tung-Chieh Chang, Shiang-Fu Huang, Chung-Jan Kang, Chun-Ta Liao, Shu-Hang Ng, Tzu-Chen Yen
BACKGROUND: Significant ethnic differences in susceptibility to the effects of chemotherapy exist. Here, we retrospectively analyzed the safety and efficacy of induction chemotherapy (ICT) with dose-modified docetaxel, cisplatin, and 5-fluorouracil (TPF) in Asian patients with borderline resectable or unresectable head and neck squamous cell carcinoma (HNSCC). METHODS: Based on the incidence of adverse events that occurred during daily practice, TPF90 (90% of the original TPF dosage; docetaxel 67...
April 25, 2016: Journal of the Formosan Medical Association, Taiwan Yi Zhi
B A Stuck, N Rothmeier, S Mattheis, N Dominas, S Lang
Over the past 20 years, the therapeutic concepts for the treatment of head and neck cancer have evolved and non-surgical treatment strategies have gained in importance. However, despite improved organ preservation protocols and primary chemoradiation, tumor recurrence is still frequent. Under these conditions, salvage surgery if often the only remaining curative treatment option. Over the past 30 years, advancements in plastic-reconstructive surgery have broadened the surgical spectrum in the head and neck area, offering new treatment options for salvage surgery in recurrent cancer of the pharynx and larynx...
May 2016: Laryngo- Rhino- Otologie
Rita Nanda, Laura Q M Chow, E Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng, Vassiliki Karantza, Laurence Buisseret
PURPOSE: Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negative breast cancer (TNBC). We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab in patients with advanced TNBC. METHODS: KEYNOTE-012 ( identifier: NCT01848834) was a multicenter, nonrandomized phase Ib trial of single-agent pembrolizumab given intravenously at 10 mg/kg every 2 weeks to patients with advanced PD-L1-positive (expression in stroma or ≥ 1% of tumor cells by immunohistochemistry) TNBC, gastric cancer, urothelial cancer, and head and neck cancer...
July 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Natale Quartuccio, Federico Caobelli, Francesca Di Mauro, Giovanni Cammaroto
PET/computed tomography with F-fluorodeoxyglucose is considered a powerful molecular imaging technique that can provide useful information in the management of patients affected by head and neck cancer. However, misleading findings have been reported because of nonspecific uptake caused by peritumoural inflammation and physiologic changes in nonmalignant tissues in the head and neck region. More specific β-emitting tracers have been introduced that can track other pathological processes. We aimed to review the existing literature performing the search until June 2015 on non-F-fluorodeoxyglucose PET tracers in head and neck cancer to highlight their role in clinical practice...
September 2016: Nuclear Medicine Communications
Lisa Hutchinson
No abstract text is available yet for this article.
June 2016: Nature Reviews. Clinical Oncology
2016-05-11 21:40:41
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"